

## REMARKS

The claims presently stand rejected under 35 USC § 103(a) as allegedly being unpatentable over the combination of FR 029878 in combination with U.S. 5,612,052 (Shalaby) in view of WO 9010441, WO 9507091, U.S. 6,150,326 (Golovistikov et al.) and SU 1061818.

FR 0298878 merely discloses that certain placental extracts contain certain fatty acids.

SU 1061818 discloses that injections of placental suspensions provide treatment for particular psoriasis. There is no disclosure of placental extracts or of fatty acids. The official action errantly speculates that the SU 1061818 suspension is an extract that contains fatty acids.

The remaining relied on art references teach vegetable extracted polyunsaturated fatty acids for treating psoriasis.

Further, the present invention comprises a topical composition for the treatment of psoriasis, whereas FR 0298878, the primary reference is devoid of any disclosure as to treatment. SU 1061818 teaches intravenous injections of a suspension (not an extract), and teaches away from the invention in this principal aspect. These several teachings away from the present invention undercut the relied on combination of SU 1061818 with FR 0298878. This relied on combination of placental extracted fatty acids with injections of placental suspensions and further with vegetable extracted topical treatments is greatly strained and pregnant with hindsight.


There is no teaching or suggestion in the prior art of a topical treatment for psoriasis that consists essentially of placental extracts having fatty acids.

Applicant submits that the claims are distinguishable over the relied on art, and the amended claim 5 and claims are in form for allowance and an early allowance is respectfully requested.

Respectfully submitted

LACKENBACH SIEGEL LLP

BY

  
MARVIN FELDMAN  
Reg. No. 25,797

MF:k  
Dated: December 15, 2004  
One Chase Road  
Scarsdale, New York 10583  
(914) 723-4300